Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

J. Shiao, K. M. Thomas, A. S. Rahimi, R. Rao, Jingsheng Yan, Xian Jin Xie, M. DaSilva, A. Spangler, M. Leitch, R. Wooldridge, A. Rivers, D. Farr, B. Haley, D. W Nathan Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: The objective is to define the therapeutic role of antiplatelet agents in a triple-negative breast cancer (TNBC) population. Methods: We performed retrospective analysis using the UTSW TNBC registry containing data from 222 Stage II–III TNBC patients treated between 1998 and 2016. Univariate analysis and multivariable logistic regression models were constructed to identify factors associated with disease-free survival (DFS), distant metastases rate (DMR), and overall survival outcomes. Antiplatelet drug use was determined by review of electronic medical records. Results: A total of 65 patients used antiplatelet (AP) agents, and 157 patients did not use AP agents. Median follow-up for AP and non-AP groups was 41.3 and 40.9 months, respectively. There was an improvement in the AP group compared with the control group in 5-year DFS (80.4% at 5 years compared with 62.3% in the control group, p = 0.04) and 5-year DMR (8.8 vs. 31.9%, p = 0.007). In multivariate analysis, AP use was found to be significantly associated with improvements in DFS and DMR. Conclusions: We illustrate that antiplatelet agent use improves DMR and DFS among a stage II and III TNBC population despite our short follow-up evaluation. Longer follow-up evaluation will be required to determine additional outcome advantage for antiplatelet agent use. Our findings support consideration of investigation of antiplatelet therapy as an adjunctive therapy for TNBC at high risk for disease recurrence.

Original languageEnglish (US)
Pages (from-to)463-471
Number of pages9
JournalBreast Cancer Research and Treatment
Volume161
Issue number3
DOIs
StatePublished - Feb 1 2017

Fingerprint

Triple Negative Breast Neoplasms
Platelet Aggregation Inhibitors
Aspirin
Disease-Free Survival
Neoplasm Metastasis
Logistic Models
Control Groups
Electronic Health Records
Population
Registries
Therapeutics
Multivariate Analysis
Survival Rate
Recurrence

Keywords

  • Anti-platelet
  • Aspirin
  • Estrogen receptor negative
  • Metastases
  • Triple negative

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. / Shiao, J.; Thomas, K. M.; Rahimi, A. S.; Rao, R.; Yan, Jingsheng; Xie, Xian Jin; DaSilva, M.; Spangler, A.; Leitch, M.; Wooldridge, R.; Rivers, A.; Farr, D.; Haley, B.; Kim, D. W Nathan.

In: Breast Cancer Research and Treatment, Vol. 161, No. 3, 01.02.2017, p. 463-471.

Research output: Contribution to journalArticle

Shiao, J. ; Thomas, K. M. ; Rahimi, A. S. ; Rao, R. ; Yan, Jingsheng ; Xie, Xian Jin ; DaSilva, M. ; Spangler, A. ; Leitch, M. ; Wooldridge, R. ; Rivers, A. ; Farr, D. ; Haley, B. ; Kim, D. W Nathan. / Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. In: Breast Cancer Research and Treatment. 2017 ; Vol. 161, No. 3. pp. 463-471.
@article{cfa446e7bfde4481a2c71587a545e3e1,
title = "Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients",
abstract = "Purpose: The objective is to define the therapeutic role of antiplatelet agents in a triple-negative breast cancer (TNBC) population. Methods: We performed retrospective analysis using the UTSW TNBC registry containing data from 222 Stage II–III TNBC patients treated between 1998 and 2016. Univariate analysis and multivariable logistic regression models were constructed to identify factors associated with disease-free survival (DFS), distant metastases rate (DMR), and overall survival outcomes. Antiplatelet drug use was determined by review of electronic medical records. Results: A total of 65 patients used antiplatelet (AP) agents, and 157 patients did not use AP agents. Median follow-up for AP and non-AP groups was 41.3 and 40.9 months, respectively. There was an improvement in the AP group compared with the control group in 5-year DFS (80.4{\%} at 5 years compared with 62.3{\%} in the control group, p = 0.04) and 5-year DMR (8.8 vs. 31.9{\%}, p = 0.007). In multivariate analysis, AP use was found to be significantly associated with improvements in DFS and DMR. Conclusions: We illustrate that antiplatelet agent use improves DMR and DFS among a stage II and III TNBC population despite our short follow-up evaluation. Longer follow-up evaluation will be required to determine additional outcome advantage for antiplatelet agent use. Our findings support consideration of investigation of antiplatelet therapy as an adjunctive therapy for TNBC at high risk for disease recurrence.",
keywords = "Anti-platelet, Aspirin, Estrogen receptor negative, Metastases, Triple negative",
author = "J. Shiao and Thomas, {K. M.} and Rahimi, {A. S.} and R. Rao and Jingsheng Yan and Xie, {Xian Jin} and M. DaSilva and A. Spangler and M. Leitch and R. Wooldridge and A. Rivers and D. Farr and B. Haley and Kim, {D. W Nathan}",
year = "2017",
month = "2",
day = "1",
doi = "10.1007/s10549-016-4081-8",
language = "English (US)",
volume = "161",
pages = "463--471",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

AU - Shiao, J.

AU - Thomas, K. M.

AU - Rahimi, A. S.

AU - Rao, R.

AU - Yan, Jingsheng

AU - Xie, Xian Jin

AU - DaSilva, M.

AU - Spangler, A.

AU - Leitch, M.

AU - Wooldridge, R.

AU - Rivers, A.

AU - Farr, D.

AU - Haley, B.

AU - Kim, D. W Nathan

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose: The objective is to define the therapeutic role of antiplatelet agents in a triple-negative breast cancer (TNBC) population. Methods: We performed retrospective analysis using the UTSW TNBC registry containing data from 222 Stage II–III TNBC patients treated between 1998 and 2016. Univariate analysis and multivariable logistic regression models were constructed to identify factors associated with disease-free survival (DFS), distant metastases rate (DMR), and overall survival outcomes. Antiplatelet drug use was determined by review of electronic medical records. Results: A total of 65 patients used antiplatelet (AP) agents, and 157 patients did not use AP agents. Median follow-up for AP and non-AP groups was 41.3 and 40.9 months, respectively. There was an improvement in the AP group compared with the control group in 5-year DFS (80.4% at 5 years compared with 62.3% in the control group, p = 0.04) and 5-year DMR (8.8 vs. 31.9%, p = 0.007). In multivariate analysis, AP use was found to be significantly associated with improvements in DFS and DMR. Conclusions: We illustrate that antiplatelet agent use improves DMR and DFS among a stage II and III TNBC population despite our short follow-up evaluation. Longer follow-up evaluation will be required to determine additional outcome advantage for antiplatelet agent use. Our findings support consideration of investigation of antiplatelet therapy as an adjunctive therapy for TNBC at high risk for disease recurrence.

AB - Purpose: The objective is to define the therapeutic role of antiplatelet agents in a triple-negative breast cancer (TNBC) population. Methods: We performed retrospective analysis using the UTSW TNBC registry containing data from 222 Stage II–III TNBC patients treated between 1998 and 2016. Univariate analysis and multivariable logistic regression models were constructed to identify factors associated with disease-free survival (DFS), distant metastases rate (DMR), and overall survival outcomes. Antiplatelet drug use was determined by review of electronic medical records. Results: A total of 65 patients used antiplatelet (AP) agents, and 157 patients did not use AP agents. Median follow-up for AP and non-AP groups was 41.3 and 40.9 months, respectively. There was an improvement in the AP group compared with the control group in 5-year DFS (80.4% at 5 years compared with 62.3% in the control group, p = 0.04) and 5-year DMR (8.8 vs. 31.9%, p = 0.007). In multivariate analysis, AP use was found to be significantly associated with improvements in DFS and DMR. Conclusions: We illustrate that antiplatelet agent use improves DMR and DFS among a stage II and III TNBC population despite our short follow-up evaluation. Longer follow-up evaluation will be required to determine additional outcome advantage for antiplatelet agent use. Our findings support consideration of investigation of antiplatelet therapy as an adjunctive therapy for TNBC at high risk for disease recurrence.

KW - Anti-platelet

KW - Aspirin

KW - Estrogen receptor negative

KW - Metastases

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=85006985041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006985041&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-4081-8

DO - 10.1007/s10549-016-4081-8

M3 - Article

C2 - 28005245

AN - SCOPUS:85006985041

VL - 161

SP - 463

EP - 471

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -